Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Sponsors Pluri

Most Recent Events

  • 05 Oct 2023 Status changed from active, no longer recruiting to discontinued. The decision to bring the Study to early clinical readout came in response to COVID-19'sevolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients.
  • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
  • 20 Dec 2022 Planned End Date changed from 1 Jun 2022 to 1 Feb 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top